Background: Identifying chronic obstructive pulmonary disease (COPD) patients at increased risk of mortality is an important component of effective disease management. Methods: A pooled analysis of patients with severe COPD, from two well-controlled 1-year studies, was conducted using Cox regression and spline analysis to evaluate predictability of baseline demographic data and in-study variables for mortality risk, and to evaluate the effect of treatment allocation to budesonide and formoterol, versus their respective control groups, on these outcomes. Results: In the pooled analysis, a Cox regression model reported a higher baseline St George's Respiratory Questionnaire (SGRQ) total score as a significant predictor of mortality (hazard ratio 1.037 [95% confidence interval 1.021e1.054]; p < 0.0001). The 36-item short-form health survey (SF-36) mental and physical component scores were also predictive of an increased mortality risk (p < 0.05). Age, forced expiratory volume in 1 s (FEV 1 ), body mass index and smoking status were not significant predictors. Spline analysis of baseline variables revealed a linear association between SGRQ total score and mortality risk over 1 year (logarithmic scale). Other baseline variables, including FEV 1 , showed different bimodal patterns in the spline analysis. There was no difference in mortality in the formoterol versus the non-formoterol treatment group while budesonide-containing treatment was associated with reduced 1-year, all-cause, in-study mortality compared with non-budesonide therapy. a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / r m e d Respiratory Medicine (2008) 102, 1615e1624
Introduction
Chronic obstructive pulmonary disease (COPD) is an increasingly important cause of morbidity and mortality worldwide and resulted in approximately 3 million deaths in 2002. 1 A number of risk factors predict an increased likelihood of COPD mortality, although their impact may vary depending on disease severity. Participation in a smoking cessation programme reduces the risk of mortality in patients with mild to moderate airway obstruction 2 whilst having a low body mass index (BMI) contributes significantly to the risk of COPD death in patients with more severe disease. 3 Other factors associated with mortality from all causes in severe and very severe COPD include forced expiratory volume in 1 s (FEV 1 ), 4 exercise capacity, 5 exacerbation frequency, 6 the Medical Research Council breathlessness score 7 and health status measured using the St George's Respiratory Questionnaire (SGRQ). 5, 8 Several of these variables have been combined to produce a grading system, known as the BMI, airflow obstruction, dyspnoea and exercise capacity (BODE) index, 9 which has stronger predictive properties than the individual components alone.
Many of the treatments used in COPD affect the factors known to predict mortality. Clinical trials lasting between 1 and 3 years have reported that combination therapy with a long-acting b 2 -agonist (LABA) and an inhaled corticosteroid (ICS) produce better lung function, fewer exacerbations and better health status than either placebo or LABA alone. 10e12 Several observational studies 13, 14 and a pooled analysis 15 have suggested that ICS therapy may reduce mortality; however, the TOwards a Revolution in COPD Health (TORCH) study showed no effect of the ICS fluticasone compared with placebo, but there was a trend for the ICS/LABA combination used to reduce mortality. 12 An apparent beneficial effect of ICS/LABA combination therapy on all-cause mortality was also suggested in a recently published 2-year controlled trial that included a treatment standardisation phase. 16 This study was undertaken to examine the relationship between the risk of death and baseline demographic and clinical factors (specifically measures of health status and lung function) as well as treatment allocation in a retrospective analysis of data from two clinical trial populations. It also examines whether these factors can identify patients at greatest risk of death and how this is affected by therapy. Furthermore, this study provides an evaluation of outcome measures that can be used to adequately power prospective studies in order to investigate the effects of ICS/LABA combinations and other therapy on mortality.
Methods Patients
The investigation described is a pooled analysis of two pivotal clinical studies, here called Study A 10 and Study B, 11 evaluating the efficacy and safety of the combination of budesonide and formoterol versus the respective components and placebo in severe COPD over a 1-year period. Patients were selected according to the following criteria: outpatients aged 40 years; COPD symptoms for 2 years; 10 pack-years' smoking history; FEV 1 /vital capacity (VC) 70%; FEV 1 50% of predicted normal (PN) measured as pre-bronchodilator values (Global Initiative for COPD [GOLD] stage III and IV); 17 use of short-acting inhaled bronchodilators for reliever medication and 1 severe COPD exacerbation within 2e12 months before the first clinic visit.
Study design and treatments
The studies were randomised, double-blind, placebo-controlled, parallel group, multicentre investigations. Both studies had a generally identical design for the 1-year treatment period but different run-in periods. Patients in Study A 10 received oral prednisolone and inhaled formoterol (Oxis â Turbuhaler â ) in addition to terbutaline (Bricanyl â Turbuhaler â ) as needed in order to standardise health status, while all maintenance medication was withdrawn from patients in Study B, 11 who only received terbutaline as needed during run-in. Terbutaline as needed was allowed as reliever medication in all treatment arms throughout the studies. Primary endpoints in both studies included the rate of exacerbations, time to first exacerbation and changes in FEV 1 . Secondary endpoints, described in full elsewhere, 10, 11 included health status measured using the disease-specific SGRQ and the generic 36-item short-form health survey (SF-36), breathlessness and other spirometry measurements in addition to FEV 1 (slow VC). Safety was evaluated by a standard question at each clinic visit, withdrawal due to disease, patients' adverse event reports and in-study mortality.
Assessments at baseline
Baseline covariates assessed for prediction of mortality risk included pre-and post-bronchodilator FEV 1 , lung function reversibility, FEV 1 /VC, age, gender, BMI, smoking status and history, and ICS or LABA use before study, as assessed at study entry. Other covariates collected at visits included health status as measured by the SGRQ and the SF-36 questionnaire at randomisation, mean breathlessness score during run-in and treatment allocation to budesonide-containing treatment (budesonide/formoterol and budesonide) versus non-budesonide treatment (formoterol and placebo) or formoterol-containing treatment (budesonide/formoterol and formoterol) versus non-formoterol treatment (budesonide and placebo).
The SGRQ and the SF-36 questionnaire were completed at recruitment (visit 1; in Study B for training purposes only) and at randomisation (visit 2) and subsequent clinic visits in both Study A and Study B. SGRQ total scores and scores from the three domains of the SGRQ (activity, symptoms and impact) were calculated. A higher score indicates deteriorating health status while a change of 4 units indicates the minimal clinically important difference relevant to patients. 8 The SF-36 score was calculated for each of its two components: the mental component summary (MCS) and physical component summary (PCS), where a lower score indicates poor health status in that component. For the reversibility test, FEV 1 was measured before and 15 min after two inhalations of terbutaline 0.5 mg and the percentage increase from baseline in FEV 1 was calculated. Serious adverse events were recorded by the investigator after the study ended. Narratives on serious adverse events and deaths, including the physician's evaluation of cause(s) of death, were obtained. Each case of death was assigned post hoc to one of the following classes: death due to an exacerbation of COPD; death due to another respiratory cause; cardiac death; vascular death; other cause (not respiratory, cardiac or vascular), or cause of death unknown. No follow-up with regard to mortality was conducted for patients who withdrew from the study and thus full intention-to-treat analysis was not possible.
Analysis
A pooled analysis was performed using the baseline covariates and the mortality data from the 1-year treatment period of Study A 10 and Study B. 11 A recent pooled analysis of seven large, well-controlled studies e the Inhaled Steroids Effects Evaluation in COPD (ISEEC) study 15 e included only the budesonide and placebo arms of Studies A and B, and so, in the current pooled analysis, a full analysis was performed of budesonide-containing arms versus non-budesonide arms and formoterol-containing treatment versus non-formoterol treatment. Descriptive statistics were used to evaluate demographic and baseline characteristics in both studies. The effect of treatment allocation on survival times was compared with a log-rank test stratified by study, and further descriptions were obtained by Cox regression, with treatment as a factor and stratification by study.
A Cox regression model stratified by study and region (Europe or non-Europe) was used to assess the predictive value of the baseline covariates. A univariate approach was chosen as the starting point because of the limited number of events, and covariates were added to the model one at a time. The p-value of the regression coefficient was used to discriminate between baseline variables, and the consistency of this approach was checked with the Bayesian information criterion. 18, 19 The most significant baseline variable was added to the model and then the process was repeated over the remaining baseline variables. Data on health status from visit 2 (after run-in) were used in the main analysis. However, an additional investigation using health status data from visit 1 (before run-in treatment intensification) in Study A was also conducted. In approximately 10% of fatal outcomes there were missing data for baseline covariates, and imputation for all missing covariates was performed using an adaptation of the multiple imputations model described by Schafer; 20 p-values and confidence intervals (CIs) were then adjusted accordingly. Penalised spline modelling 21 was used to describe the form of the relationship between clinical covariates and mortality on the logarithmic scale, i.e. to investigate possible deviations from a pure linear relationship, the most known non-linear relationship probably being the J-or U-shaped association between BMI and risk of death. 22 The possibility of timevarying effects were also assessed using a proportional hazards model. 23 KaplaneMeier curves were used to illustrate the effect of treatment allocation on mortality.
Results

Baseline characteristics and patient population
The baseline demographic and clinical characteristics of the pooled study population (n Z 1834) are presented in Table 1 . The 1-year studies were completed, according to protocol, by 1166 patients, of whom 1083 were in-study at day 360 and 840 were in-study at day 365. A total of 668 patients did not complete the studies (due to COPD worsening, other adverse events or other reasons) and 56 patients died during the course of the studies. The placebo group had the largest number of dropouts ( Fig. 1) , with the budesonide/formoterol combination group showing the lowest drop-out rate. In Study A the budesonide group showed a lower withdrawal rate than placebo and the formoterol group had a similar rate of withdrawal to placebo while in Study B the withdrawal rates in the formoterol and budesonide groups were similar, showing a pattern closer to the rate of withdrawal with budesonide/formoterol than to the higher rate with placebo ( Fig. 1 ).
Mortality rates
There were fewer deaths among those receiving budesonide-containing therapy (budesonide alone or budesonide/ formoterol combination), with 22 of the total 56 deaths over the 1-year treatment period in the pooled studies occurring in this group and 34 occurring in the non-budesonide group (p Z 0.036 by log-rank test). Cox regression analysis with stratification by study only showed a hazard ratio (HR) of 0.564 in favour of the budesonide group (95% CI 0.327e 0.972; p Z 0.039; Fig. 2A ). COPD was the leading cause of mortality, with six deaths occurring in the budesonide group versus 16 deaths in the non-budesonide group (Table 2i) . Deaths from other respiratory causes occurred in equal numbers in budesonide and non-budesonide treatment groups (three patients in each group), and in similar numbers in formoterol and non-formoterol groups (two and four patients respectively). The risk of cardiac death was similar between groups (five patients in both budesonide and non-budesonide treatment groups, six patients in the formoterol group and four in the non-formoterol treatment group; Table 2i ). The distribution of deaths from any cause between formoterolcontaining and non-formoterol treatments was 31 and 25, respectively (of which 12 versus 10 were COPD deaths, respectively; Table 2ii ) (HR 1.102 [95% CI 0.648e1.875]; p Z 0.720) ( Fig. 2B ).
Baseline covariates as predictive factors for mortality
Using Cox regression modelling, the SGRQ total score and the SGRQ impact score were the most significant baseline predictors of mortality (p < 0.0001) ( Table 3 ). The SGRQ activity score, SF-36 MCS, SF-36 PCS and SGRQ symptom score were additional significant predictors of mortality (all p < 0.05) while breathlessness, age, lung function measured as pre-and post-bronchodilator FEV 1 (actual and percentage PN), reversibility, BMI and smoking history or status were not predictive ( Table 3 ). In a separate analysis on the value of treatment allocation as a predictor of mortality, budesonide-containing treatment was found to decrease the risk of death, with the p-value retaining significance after adjustment for SGRQ total score (HR 0.542 [95% CI 0.312e0.942]; p Z 0.03). On adjustment both for SGRQ total score and for allocation to budesonide treatment, all other predictors of mortality became non-significant. KaplaneMeier curves showed improved survival in patients receiving budesonide-containing treatment, with prominent separation between budesonide versus non-budesonide treatments among those with higher SGRQ total scores (Fig. 2C ). Allocation to formoterol-containing treatment showed a similar mortality distribution as non-formoterol therapy in the whole population ( Fig. 2B) with little separation between treatments at higher SGRQ scores (Fig. 2D ).
Proportion of patients in study
After 1 year, a four-point higher SGRQ baseline score was associated with a 15.7% increase (95% CI 8.8e23.2) in the risk of all-cause mortality as calculated by standard Cox regression. Using SGRQ data from visit 1 in Study A, i.e. before treatment intensification, did not change the power of SGRQ total score as a predictor of mortality. A proportional hazards model with baseline SGRQ total score as time-varying effect indicated that the mortality risk associated with SGRQ total score increased linearly over time before reaching a plateau at around 6 months, signifying that there is a maintained high mortality risk at high SGRQ levels (Fig. 3) .
Penalised spline modelling of baseline covariates indicated a linear relationship between the disease-specific health status assessment tool, SGRQ total and impact scores, and the risk of mortality over the entire range of SGRQ scores (Fig. 4A,B) . This observation was supported by spline analysis of the general health status assessment tool SF-36 which showed a linear relationship over the major part of the interval (not shown). Age appeared to be associated with a bimodal distribution of risk (Fig. 4C) , with a plateau between 60 and 80 years, while BMI had a U-shaped risk distribution with the lowest risk at a BMI of approximately 30 (Fig. 4D ). Although observations were outside the significance level, the spline analysis of lung function variables indicated that there was a linear association between declining lung function and A B C D Figure 2 KaplaneMeier curves for mortality. KaplaneMeier curves for mortality for budesonide versus reference (non-budesonide) groups (A) and formoterol versus reference (non-formoterol) groups (B), including stratification by St George's Respiratory Questionnaire (SGRQ) total score (C,D). (A) Survival curves in the budesonide-treated patients (budesonide/formoterol and budesonide) versus the reference group (formoterol and placebo), showing separation between the two groups in favour of budesonidetreated patients. (C) Budesonide versus reference (non-budesonide) treatment groups separated by the median cut-off in SGRQ total score of 50 points, demonstrating that the majority of deaths occurred among patients with an SGRQ total score >50 points and who were not treated with budesonide-containing therapy. (B) Survival curves for the formoterol-treated population (budesonide/formoterol and formoterol) versus the reference group (budesonide and placebo), with no difference in mortality rates indicated. (D) This may indicate a minor separation between the formoterol and reference (non-formoterol) groups, in patients with very poor health status (SGRQ total score >50 points). mortality risk for FEV 1 above 1.2 l (pre-bronchodilator) while below this level there was no further discriminative predictive value (Fig. 4E ). Spline analysis of FEV 1 PN values showed a different pattern with a distinct plateau in the range between approximately 30 and 60% in post-bronchodilator FEV 1 and an apparent increased risk below 30% (Fig. 4F) . The pre-bronchodilator FEV 1 PN showed a similar curve ( Fig. 4G) , indicating that bronchodilator response may play a role. The spline curve for reversibility ( Fig. 4H ) supports this observation, showing a linear relationship between mortality risk and decreasing bronchodilator response. Gender and ICS and/or LABA use at study entry were analysed separately as there were zero cases in some strata, but results indicated that these factors were of less predictive value. 
Discussion
This pooled analysis reports that poor baseline health status, as indicated by SGRQ and SF-36 scores, is a significant predictor of mortality in patients with severe COPD, with SGRQ total score emerging as the strongest predictor compared with other baseline covariates.
Improvement of health status in COPD patients is one of the key treatment goals according to GOLD management guidelines. 17 However, the difficulties associated with quantifying a clinically important improvement in day-to-day practice are well-recognised. This study used baseline values as predictors of mortality over a 1-year period and reports that mortality was higher in patients with high SGRQ scores at randomisation. The linear relationship observed in the spline analysis shows that there is in fact an exponential relationship between health status and risk of death as the data were logarithmically transformed. The SGRQ measurement is known to be a valuable means of consistently assessing deteriorating health status in patients with moderate to very severe COPD 24 and, while several studies have reported the disease-specific SGRQ 25 as being predictive of mortality in COPD, 5, 8, 26, 27 this is one of the few studies to report that the generic SF-36 questionnaire can also be useful for identifying vulnerable patients. 25 Conventionally, COPD is defined as mild, moderate or severe, based on measures of lung function. 17 Although a relationship has been reported between low FEV 1 and mortality, 4, 26, 28 spline analysis performed in the present study suggests that FEV 1 was only discriminative in prediction of mortality risk when FEV 1 had not fallen below 1.2 l (pre-bronchodilator) (Fig. 4) . Bronchodilator response, on the other hand, showed a linear correlation with mortality risk, with a lower risk in the more responsive patients (Fig. 4) . Our population had a mean FEV 1 of 0.99 l, with an inclusion criterion of pre-bronchodilator FEV 1 50%, suggesting that FEV 1 is indeed a predictor of mortality in patients with moderate, but not severe, COPD but may also be linked to the degree of reversibility, which in this study had a mean value of 5.8%. These observations are descriptive in nature and warrant further investigation in larger studies. Increasing age is known to be associated with mortality risk, 25, 26 and spline analysis showed a linear relationship from 40 to 60 years but a constant risk profile of mortality from 60 to 80 years in the study. BMI had a Ushaped distribution of risk, which has been observed in other studies 3, 22 and is consistent with reports that a lower BMI is linked to increased mortality risk. 25, 28, 29 SGRQ total score was the most informative baseline variable in the spline analysis, demonstrating a linearly increasing mortality risk from 0 to 100 points. This baseline variable was also a significant predictor of mortality while the other baseline variables, described above, remain exploratory. The SF-36 questionnaire also showed a linearly distributed risk prediction over the major part of the interval, in both the PCS and the MCS, which levelled out in very severe COPD, but support the use of health status measurement in identifying patients at risk. Although lung function is routinely measured in clinical practice, and bronchodilator response may be of some guidance, these findings support existing evidence that health status is a better predictor of admission to hospital and death within 12 months than FEV 1 30 and suggest that health status assessment should become standard in COPD management.
A recent meta-analysis conducted by Salpeter and colleagues 31 suggested that LABA may compromise the long-term safety of COPD patients. This is, however, not consistent with the findings of the current study, nor with the results from a large, 3-year controlled study in COPD with all-cause mortality as the primary outcome. 12 Indeed, the LABA treatment group in the TORCH study 12 had the lowest incidence of cardiovascular deaths among all treatment arms including placebo.
The benefit of budesonide in reducing 1-year all-cause mortality in this study is in agreement with previous observational studies suggesting a benefit of ICS therapy in reducing COPD mortality 13, 14, 32 and a pooled analysis of seven large controlled trials. 15 The ISEEC study included data on budesonide and placebo arms from the material presented in this analysis and reported approximately a 25% reduction in mortality with ICS compared with placebo. 15 The present results are also in agreement with data from the 3-year European Respiratory Society's study on Chronic Obstructive Pulmonary Disease (EUROSCOP). 33 The EUROSCOP data were not included in the current study because of differences in baseline data, including a lack of health status measurements, although all-cause mortality data are supportive when included in the Cox regression analysis. Furthermore, the TORCH study 12 although there was a reduction in mortality risk with ICS/ LABA combination therapy. In this study, mortality from ICS therapy alone was a secondary endpoint but the completeness of the follow-up to death strengthens its conclusions. Whether similar data to those reported here would be observed in patients from the TORCH study with similar impairments in health status remains to be determined. Another 2-year study of an ICS/LABA combination therapy in severe COPD patients reported a lower mortality rate with combination therapy compared with tiotropium. However, this study did not examine the effects of ICS alone, mortality was a tertiary outcome and the vital status of patients who did not complete the study was not determined. 16 Further investigation into the potential mortality benefit of ICS or ICS/LABA combinations is required. 34 The current pooled analysis has several limitations. Studies A and B were not designed to investigate mortality and patients with co-morbidities or recent exacerbations Penalised splines for covariates at baseline as predictors of mortality, evaluated on a logarithmic scale. Each panel shows the shape of the association between the respective baseline covariate and risk of mortality over 1 year. The disease-specific health status instrument, St George's Respiratory Questionnaire (SGRQ impact score, A), shows a linear association with deteriorating health status throughout the full interval, thus showing full discriminative predictive value throughout the range. The SGRQ total score (B) also shows a linear association throughout the full interval. The spline of age distribution indicates an apparently increasing risk of death in the interval between 40 and 60 years, but a constant association in the interval 60e80 years (C). A U-shaped association can be observed between body mass index (BMI) and mortality (D), which confirms the findings of previous studies. 22 (E) Linear association between lung function and mortality in moderate disease, but no discriminative association is observed when lung function has fallen below approximately 1.2 l (pre-bronchodilator value). (F) Mortality risk profile of post-bronchodilator predicted normal (PN) forced expiratory volume in 1 s (FEV 1 ), with an increasing risk below 30% while in the interval 30e60% there seems to be little predictive value. (G) Pre-bronchodilator FEV 1 (% of PN). (H) Apparent predictive correlation between poor lung function reversibility and increasing mortality risk.
(within 1 month prior to study start) were excluded. There was also no post-withdrawal follow-up, so only data on in-study mortality are provided. It has recently been reported that differential discontinuation in randomised trials is related to disease severity or progression and can have profound effects on the interpretation of mortality data in intention-to-treat analyses unless the vital status of all trial participants is known at the end of the trial period. 35 Additionally, since mortality was a secondary outcome measure, data on the cause of death were not listed according to a pre-defined protocol, and each case may have several causes listed. This retrospective study is further limited by the difference in the run-in phases in Study A and Study B. 10, 11 The drop-out rate due to disease deterioration during the run-in phase was lower in Study A (31/1141 enrolled) than in Study B (75/980 enrolled) because of treatment intensification during run-in. Furthermore, 48 versus 26% of patients in Study A and Study B, respectively, were treated with ICS before randomisation. Thus, it is possible that more steroid-dependent patients were randomised in Study A due to the treatment intensification during run-in, while Study B may have shown a healthy survivor bias since maintenance medication, including ICS, was withdrawn during run-in, resulting in a larger drop-out rate during this phase. 10, 11 These limitations reflect the difficulties associated with retrospective determination of mortality risk.
Health status, as measured by the SGRQ total score, is an important baseline variable for predicting in-study mortality. This knowledge should allow future studies using COPD mortality in clinical trials as an outcome to identify a highrisk population in whom the effect of treatment can be best studied. Although currently designed for use in clinical trials, health status assessment tools such as the SGRQ may provide important information on COPD patients at increased risk of death in daily clinical practice. The development of a more readily applicable tool would greatly help the application of this approach.
